It did not correlate with IPI score (p=0.97), double/triple expressor or high-grade B cell lymphoma with Myc and Bcl2 translocations (p=0.94), disease stage (p=0.97), localized vs. extensive disease (p=0.41), receipt of systemic therapy with bRT (p=0.5), bRT timing pre- or post-leukapheresis (p=0.9), bRT dose of ≥30 Gy (p=0.28), or receipt of comprehensive or focal bRT (p>0.9). Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.